Ahead of what could be a major milestone at the 55th Annual Meeting of the American Society of Hematology, Cyclacel's (CYCC) stock price has risen steadily as I predicted it would. The pace of appreciation has been in lockstep with a steady drumbeat of good news over the past several months.
That trend is likely to continue, but before I make the case for an explosive move to the upside, I want to briefly address a change to my investment philosophy that has implications far beyond my risk profile as it will impact the number of articles I author here on Seeking Alpha.
Many professional advisors caution that a balanced portfolio across multiple sectors is...
Only subscribers can access this article, which is part of the PRO research library covering 3,589 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: